|
|
|
| Expression of PTEN in endometrial disease of patients taking Tamoxifen after breast cancer operation |
| LI Yuhe HE Yue WU Yumei |
| Department of Gynecological Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 10006, China |
|
|
|
Abstract Objective To evaluate the expression of PTEN protein in endometrial disease of patients taking Tamoxifen (TAM) after breast cancer operation, and to explore its relationship with TAM-related endometrial disease on a molecular level. Methods From January to December 2018，56 cases with breast cancer receiving TAM (20 mg/d) after surgery in Beijing Obstetrics and Gynecology Hospital, Capital Medical University were selected. Among them, 10 cases with irregular vaginal bleeding or regular B-ultrasound follow-up showed abnormal thickening of the endometrium which were hospitalized for hysteroscopic curettage to obtain endometrium specimens were named as TAM group after breast cancer operation. At the same time, 10 cases with whole hysterectomy normal endometrium of “the cervical intraepithelial neoplasia grade Ⅲ or uterine fibroids” were named as normal endometrium group. 10 cases withⅠ type of endometrial adenocarcinoma were named as endometrial cancer group. Normal endometrial group and endometrial cancer group were control group. Immunohistochemistry was used to determine the expression of PTEN protein in endometrial tissues of patients in 3 groups. Results The quantitative expression of PTEN protein in the three groups were significantly different (P < 0.05). The quantitative expression of PTEN protein in endometrial cancer group was lower than that in normal endometrial group, and the difference was statistically significant (P < 0.05). The expression intensity of endometrial cancer group was lower than that of normal endometrial group, and the expression intensity of TAM group after breast cancer operation was lower than that of normal endometrial group. Conclusion The PTEN gene may used as an early molecular marker for predicting TAM-associated endometrial disease, and its mutation may play an important role in the development of TAM-associated endometrial disease.
|
|
|
|
|
|
[1] Burstein HJ，Prestrud AA，Seidenfeld J，et al. American Society of Clinical Oncology clinical practice guideline：update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer [J]. J Clin Oncol，2010，28（23）：3784-3796.
[2] Beelen LR，Gallee MPW，Hollema H，et al. Risk and Prognosis of Endometrial Cancer After Tamoxifen for Breast Cancer [J]. Obstet Gynecol Surv，2001，56（2）：90-91.
[3] Risinger JI，Hayes AK，Berchuck A，et al. PTEN/MMAC1 Mutations in Endometrial Cancers [J]. Cancer Res，1997， 57（21）：4736-4738.
[4] 李贺，郑荣寿，张思维，等.2014年中国女性乳腺癌发病与死亡分析[J].中华肿瘤杂志，2018，40（3）：166-171.
[5] Shi XJ，Au WW，Wu KS，et al. Mortality characteristics and prediction of female breast cancer in China from 1991 to 2011 [J]. Asian Pac J Cancer Prev，2014，15（6）：2785-2791.
[6] 王一同，张振华，卢雯平，等.中医体质学在乳腺癌防治中的应用价值[J].中国医药，2017，12（6）：901-904.
[7] 徐陌，陈志军，桂照华，等.饮酒促进TA2小鼠乳腺癌的发生及机制探讨[J].中国实验动物学报，2017，25（5）：563-566.
[8] Figg WD，Cook K，Clarke R，et al. Aromatase inhibitor plus ovarian suppression as adjuvant therapy in premenopausal women with breast cancer [J]. Cancer Biol Ther，2014，15（12）：1586-1587.
[9] 林伟强.他莫昔芬联合托瑞米芬对晚期乳腺癌近期生活质量的影响[J].中国医药科学，2017，7（20）：48-50，68.
[10] 虞宝中，贺汉军，侯艾林，等.来曲唑与他莫昔芬对绝经后乳腺癌切除术患者的治疗效果及其对子宫内膜厚度与子宫内膜病变的影响[J].中国医药，2017，12（10）：1565-1568.
[11] 江布英，吴耀忠，郭梓耘，等.他莫昔芬对绝经前后乳腺癌患者子宫内膜的影响[J].中国医药科学，2018，8（24）：79-82.
[12] 王宏阳，李学英，潘有福，等.雌激素及拮抗剂他莫昔芬在肝癌发生发展中的作用和分子机制的研究进展[J].医学综述，2018，24（6）：1077-1081，1086.
[13] 李俊杰，邵志敏.2018年美国《国家综合癌症网络乳腺癌临床实践指南》解读[J].中华乳腺病杂志：电子版，2018，12（3）：129-134.
[14] Davies C，Pan H，Godwin J，et al. Long-term effects of continuing adjuvant Tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer：ATLAS，a randomised trial [J]. Lancet，2013，381（9869）：805-816.
[15] Jones ME，van Leeuwen FE，Hoogendoorn WE，et al. Endometrial cancer survival after breast cancer in relation to tamoxifen treatment：pooled results from three countries [J]. Breast Cancer Res，2012，14（3）：R91.
[16] Assikis VJ，Jordan VC. Tamoxifen and endometrial cancer：from experiment to patient [J]. Recent Results Cancer Res，1996，140：61-71.
[17] 马雅茹，阿艳妮，张丽芳，等.miR-17-5p和PTEN在子宫内膜癌中的表达及意义[J].中国妇幼保健，2018，33（19）：4512-4516.
[18] Steck PA，Pershouse MA，Jasser SA，et al. Identification of a candidate tumour suppressor gene，MMAC1，at chromosome 10q23.3 that is mutated in multiple advanced cancers [J]. Nat Genet，1997，15（4）：356-362.
[19] Lacey JV，Yang H，Gaudet MM，et al. Endometrial cancer and genetic variation in PTEN，PIK3CA，AKT1，MLH1，and MSH2 within a population-based case-control study [J]. Gynecol Oncol，2011，120（2）：167-173.
[20] Sun H，Enomoto T，Fujita M，et al. Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia [J]. Am J Clin Pathol，2001，115（1）：32-38.
[21] Levine RL，Cargile CB，Blazes MS，et al. PTEN mutations and microsatellite instability in complex atypical hyperplasia，a precursor lesion to uterine endometrioid carcinoma [J]. Cancer Res，1998，58（15）：3254-3258.
[22] Mutter GL，Lin MC，Fitzgerald JT. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers [J]. J Natl Cancer Inst，2000，92（11）：924-930.
[23] Holtz D，Ramondetta LM，Burke TW，et al. PTEN expression in Tamoxifen-associated endometrial cancers [J]. Anticancer Res，2002，22（5）：2945-2948.
[24] Prasad M，Wang H，Douglas W，et al. Molecular genetic characterization of Tamoxifen-associated endometrial cancer [J]. Gynecol Oncol，2005，96（1）：25-31.
[25] 郭蕾，李文君，马雪莲，等.他莫昔芬介导的绝经期子宫内膜pten基因突变的检测[J].首都医科大学学报，2012， 33（1）：30-35.
[26] 马雪莲，贾弘禔，冯力民.MicroRNA-1297靶向沉默PTEN基因的表达参与TAM诱发子宫内膜癌机制的研究[C]//北京医学会&北京医师协会.2013北京地区妇产科学术年会论文集.2013：158-159. |
|
|
|
